| 1 |
Zhang Y, Li R, Gu Y, LiZhu Y, Liu X, Zhang S. Clinical, Laboratory, Histological, Radiological, and Metabolic Features and Prognosis of Malignant Pleural Mesothelioma. Medicina (Kaunas) 2022;58. [PMID: 36557076 DOI: 10.3390/medicina58121874] [Reference Citation Analysis]
|
| 2 |
Ghanim B, Baier D, Pirker C, Müllauer L, Sinn K, Lang G, Hoetzenecker K, Berger W. Trabectedin Is Active against Two Novel, Patient-Derived Solitary Fibrous Pleural Tumor Cell Lines and Synergizes with Ponatinib. Cancers (Basel) 2022;14. [PMID: 36428694 DOI: 10.3390/cancers14225602] [Reference Citation Analysis]
|
| 3 |
Faccioli E, Terzi S, Giraudo C, Zuin A, Modugno A, Labella F, Zambello G, Lorenzoni G, Schiavon M, Gregori D, Pasello G, Calabrese F, Dell’amore A, Rea F. Sarcopenia as a Predictor of Short- and Long-Term Outcomes in Patients Surgically Treated for Malignant Pleural Mesothelioma. Cancers 2022;14:3699. [DOI: 10.3390/cancers14153699] [Reference Citation Analysis]
|
| 4 |
Rovers S, Janssens A, Raskin J, Pauwels P, van Meerbeeck JP, Smits E, Marcq E. Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma. Biomedicines 2022;10:673. [PMID: 35327475 DOI: 10.3390/biomedicines10030673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 5 |
Harber J, Kamata T, Pritchard C, Fennell D. Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy. J Immunother Cancer 2021;9:e003032. [PMID: 34518291 DOI: 10.1136/jitc-2021-003032] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 6 |
Pouliquen DL, Kopecka J. Malignant Mesothelioma. Cancers (Basel) 2021;13:3447. [PMID: 34298661 DOI: 10.3390/cancers13143447] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 7 |
Lorenzini E, Ciarrocchi A, Torricelli F. Molecular Fingerprints of Malignant Pleural Mesothelioma: Not Just a Matter of Genetic Alterations. J Clin Med 2021;10:2470. [PMID: 34199544 DOI: 10.3390/jcm10112470] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 8 |
Huang Y, Meng Q. [Research Progress of Immune Checkpoint Inhibitors
in Malignant Pleural Mesothelioma]. Zhongguo Fei Ai Za Zhi 2021;24:441-6. [PMID: 34157803 DOI: 10.3779/j.issn.1009-3419.2021.102.18] [Reference Citation Analysis]
|
